Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Recurrence 1Lymphoma, T-Cell, Cutaneous 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Cytarabine 21Imatinib Mesylate 20venetoclax 16Azacitidine 16nilotinib 15Cyclophosphamide 15fludarabine 13Dasatinib 12blinatumomab 10Rituximab 10quizartinib 7Gemtuzumab 7Daunorubicin 7ruxolitinib 6Drug Therapy 6Clofarabine 6Bendamustine Hydrochloride 6AP 1903 reagent 6ponatinib 5fludarabine phosphate 5Whole-Body Irradiation 5Vincristine 5Mycophenolic Acid 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Dexamethasone 5vosaroxin 4revumenib 4rasburicase 4forodesine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia × sapacitabine × Clear all
NCT00380653 2021-12-13

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

Cyclacel Pharmaceuticals, Inc.

Phase 1 Completed
47 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡